Collegium Pharmaceutical Q2 2025 Earnings Report

Collegium Pharmaceutical EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.88
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Collegium Pharmaceutical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $182.26 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Collegium Pharmaceutical Announcement Details

• Quarter: Q2 2025
• Date: 8/6/2025
• Time: After Market Closes
• Conference Call Date: Thursday, August 7, 2025
• Conference Call Time: 4:30PM ET

Collegium Pharmaceutical (NASDAQ:COLL) is a specialty pharmaceutical company focused on the development and commercialization of improved therapies for patients suffering from pain. The company’s core business revolves around creating and marketing abuse-deterrent and extended-release opioid formulations designed to address the clinical complexities of chronic pain management while mitigating risks associated with opioid misuse. Through its proprietary DETERx platform, Collegium aims to deliver consistent, controlled drug release and reduced potential for tampering or diversion.

The company’s flagship product, Xtampza ER, is an extended-release oxycodone capsule approved for the management of chronic, moderate to severe pain in patients requiring continuous, long-term opioid treatment. Beyond Xtampza ER, Collegium maintains an active development pipeline of additional formulations built on its DETERx technology, targeting both oral and potential non‐oral delivery routes. The company also invests in clinical and real-world studies to demonstrate the safety, efficacy, and abuse-deterrent properties of its product candidates, supporting prescriber confidence and payer access.

Founded in 2013 as a spin-out from Rhodes Technologies, Collegium Pharmaceutical is headquartered in Wilmington, North Carolina, and serves patients and healthcare providers across the United States. Over the years, the company has expanded its commercial infrastructure, establishing sales and medical affairs teams dedicated to pain management. Collegium is led by Chief Executive Officer Michael Thomas and a management team with deep expertise in pharmaceutical development, regulatory affairs, and commercial strategy, underscoring its commitment to advancing patient-centered pain therapies.